XML 26 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
OTHER (INCOME)/EXPENSE, NET
 12 Months Ended
Dec. 31, 2024
Other Nonoperating Income (Expense) [Abstract]  
OTHER (INCOME)/EXPENSE, NET OTHER (INCOME)/EXPENSE, NET
 Year Ended December 31,
Dollars in millions202420232022
Interest expense$1,947 $1,166 $1,232 
Royalty income - divestitures (Note 4)(1,104)(862)(832)
Royalty and licensing income (Note 4)(736)(1,488)(1,283)
Provision for restructuring (Note 6)635 365 75 
Investment income(478)(449)(171)
Integration expenses (Note 6)284 242 440 
Litigation and other settlements (a)
84 (390)178 
Acquisition expense
50 32 — 
Intangible asset impairment
47 29 — 
Equity investment (gains)/losses, net (Note 9)
(16)160 801 
Loss on debt redemption (Note 10)
— — 266 
Divestiture losses/(gains) (Note 4)
15 — (211)
Other(b)
165 37 81 
Other (income)/expense, net
$893 $(1,158)$576 
(a)    Includes $90 million of income related to the Eisai collaboration termination incurred in 2024.
(b)    Includes pension settlement charges of $119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan.
Litigation and Other Settlements

BeiGene Settlement

In 2023, BMS and BeiGene, Ltd. ("BeiGene") entered into an agreement that terminated all contractual relationships and settled all on-going disputes and claims between the parties, including those related to the Abraxane license and supply agreements and related arbitration proceedings that were previously disclosed.

As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $322 million of expense that was included in Other (income)/expense, net in 2023. The expense was determined based on the closing price of the shares on the date of the transfer.

AstraZeneca Settlement

In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $418 million, of which the net present value of $384 million was reflected in Other (income)/expense in 2023.

Nimbus Change of Control Income

In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10% of any change in control proceeds received by Nimbus related to its TYK2 inhibitor. In 2023, Takeda acquired 100% ownership of Nimbus' TYK2 inhibitor for approximately $4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $2.0 billion. As a result, $400 million of income related to the change of control provision was included in Other (income)/expense in 2023.